Key facts
- Edesa Biotech reported favorable exploratory data for paridiprubart.
- Paridiprubart is a first-in-class anti-TLR4 monoclonal antibody.
- The data pertains to patients with acute kidney injury and respiratory distress.
- Edesa Biotech develops therapeutics for immuno-inflammatory diseases.
Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, has announced favorable exploratory data for its drug candidate, paridiprubart. Paridiprubart is described as a first-in-class anti-TLR4 monoclonal antibody. The positive data was observed in patients diagnosed with acute kidney injury (AKI) and respiratory distress. The company's focus is on creating novel treatments for a range of immuno-inflammatory conditions.